Oralomide Opportunity Target pharmaceutical partnerships and licensing discussions around olorofim, leveraging its unique DHODH mechanism and broad anti-mould activity to position F2G as a leader in life-threatening invasive fungal infections.

Clinical Momentum Leverage the completion of global Phase 3 enrollment (OASIS) and regulatory designations (EMA orphan drug, FDA QIDP and Breakthrough Therapy) to engage with academic medical centers, hospitals, and CROs for potential expansion, compassionate use programs, or post-approval studies.

Strategic Collaborations Explore co-development or regional commercialization partnerships in the US, Europe, and Austria to accelerate market access, share clinical trial costs, and extend geographical reach given F2G’s multi-country presence.

Public Health Demand Position olorofim as a differentiated solution for resistant mould infections where current therapies are limited, targeting infectious disease networks, transplant centers, and ICU wards with high-risk patient cohorts to drive early adoption and payer engagement.

Expansion Readiness Highlight the company’s manufacturing scalability, global trial footprint, and orphan/QIDP designations to attract investors, distributors, and contract manufacturers for scalable supply and timely global access.